ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025
APOE4 modulates the association between DTI-ALPS index and Alzheimer's pathologies.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Association between obstructive sleep apnea severity and glymphatic-related DTI-ALPS alterations in newly diagnosed, Drug-Naïve Alzheimer's disease.The journal of prevention of Alzheimer's disease · 2026Article
- Serial failure of the brain clearance continuum in Alzheimer's disease: mechanisms and therapeutic perspectives.Journal of neurology · 2026Review
- APOE4 modulates the association between DTI-ALPS index and Alzheimer's pathologies.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionDiffusion-tensor imaging (DTI) analysis along the perivascular space (ALPS) has emerged as a non-invasive marker of glymphatic function. Preclinical studies suggest that apolipoprotein E4 (APOE4), a major genetic risk factor for Alzheimer's disease, may exacerbate glymphatic dysfunction-related accumulation of beta-amyloid (Aβ) and tau, but human evidence is lacking. This study examined whether APOE4 moderates the relationship between glymphatic dysfunction, estimated by the ALPS index, and Aβ or tau deposition.
methodsWe analyzed 423 older adults (mean age 70.5 ± 8.1 years) with varying cognitive profiles who underwent DTI to calculate the ALPS index and [
resultsA significant interaction between APOE4 status and ALPS index was observed for Aβ deposition, but not for tau. A lower ALPS index was associated with higher Aβ only in APOE4-positive individuals. DISCUSSION: APOE4 enhances the association between glymphatic dysfunction and Aβ burden. HIGHLIGHTS: Apolipoprotein E4 (APOE4) status moderates the link between analysis along the perivascular space (ALPS) index and cerebral beta-amyloid. Lower ALPS index is associated with higher beta-amyloid (Aβ) only in APOE4 carriers. No significant moderation by APOE4 on ALPS-tau association was found. ALPS index may offer non-invasive glymphatic marker for beta-amyloid burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.